Last reviewed · How we verify

NCT05242666: IMAGE-DCM

Quantiative MRI and Myelin-PET for the Assessment of Degenerative Cervical Myelopathy

Status unknown NA Last updated 27 May 2022
What this trial tests

NA trial testing 3T MR Imaging of the cervical spinal cord in Cervical Spondylosis With Myelopathy in 100 participants. Status unknown.

Timeline
17 April 2021
Primary endpoint
1 February 2025
1 February 2025

Quick facts

Lead sponsorCambridge University Hospitals NHS Foundation Trust
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment100
Start date17 April 2021
Primary completion1 February 2025
Estimated completion1 February 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Who can join

18 and older, any sex, with Cervical Spondylosis With Myelopathy or Degenerative Cervical Myelopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To use advanced imaging techniques, including MRI Brain and Spinal Cord, and MRI/PET Spinal Cord to provide an assessment of Degenerative Cervical Myelopathy to improve understanding of the pathophysiology and natural history of DCM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cervical Spondylosis With Myelopathy

Currently open trials in the same condition.

Other Cambridge University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05242666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing